What to Expect at a SPRAVATO® Appointment: Monitoring, Timing, and Questions to Ask

SPRAVATO® appointment: hand holding a nasal spray device against white blossoms

If you are researching what to expect at a SPRAVATO® appointment, it helps to know that the visit is not designed to be rushed. You will need time to check in, receive SPRAVATO® in person, rest under observation, and make a safe plan for getting home. Knowing that structure ahead of time can make the day feel more manageable.

At Mental Ease Psychiatry, we want you to understand what the visit requires before you schedule. A conversation about SPRAVATO® begins with your health history, current medications, physical health, goals, and practical needs. Our psychiatric evaluation gives us space to understand those details rather than treating the appointment as a simple prescription pickup.

The appointment includes more than the nasal spray

SPRAVATO® is administered in person in a clinical setting. The medication portion is only one part of the appointment. There is also preparation, monitoring, and recovery time before you leave.

Before treatment, we will review relevant changes since your last visit. That can include new medications, missed doses of other prescriptions, alcohol or substance use, illness, sleep changes, and symptoms that have felt important since you were last here. Bring an updated medication and supplement list, even if you think nothing has changed. Careful review matters because medication dosing and monitoring require attention to the full clinical picture, as guidance on psychotropic dosing and monitoring emphasizes (DeBattista et al., 2024).

We may also check your blood pressure before administration. SPRAVATO® can temporarily increase blood pressure, so those readings matter. Tell us about high blood pressure, heart or blood vessel concerns, headaches, pregnancy, or a new medical issue. If something has changed between appointments, it is better to mention it than to assume it is unrelated.

Once you receive SPRAVATO®, you remain with us for observation. This is quiet time. It is not a time to drive, work, make major decisions, or plan an errand afterward.

What to expect at a SPRAVATO® appointment during monitoring

Some people experience sleepiness, dizziness, nausea, a sense of disconnection, or temporary changes in perception or thinking during and after SPRAVATO®. Experiences differ from person to person. They can also differ from one appointment to the next. Monitoring allows us to check on how you are feeling and respond if you need support.

The observation period is generally at least two hours. We will let you know when you are ready to leave based on the visit and your condition that day. SPRAVATO® is given under clinical supervision because sedation, dissociation, and blood-pressure changes can occur. Remaining in the clinic gives you a supported setting while those effects are monitored.

You may find it helpful to bring something low-stimulation for the observation period. Headphones, calming music, a podcast, or a sweater can make the time more comfortable. Some people prefer to sit quietly. There is no correct way to use that time. The goal is to give your mind and body room to settle while our team remains available.

Monitoring is not an inconvenience added to the appointment. It is a central part of the care process. Our nasal spray service is built around that in-person clinical structure.

Plan for a longer visit and a ride home

Set aside the full appointment window. Do not schedule SPRAVATO® between meetings, before school pickup, or on a day when you need to drive yourself home. You will need a trusted adult to take you home after the visit, or another reliable transportation arrangement that does not require you to drive.

After receiving SPRAVATO®, do not drive, operate machinery, or do anything that requires full alertness until the next day after a restful night’s sleep. Plan for that before your visit. Do not wait until the end of the appointment to decide whether you feel well enough to drive.

A few practical steps can make the day smoother:

  • Arrange your ride before arriving, including a backup plan if possible.
  • Eat and drink according to the instructions we give you before your appointment.
  • Wear comfortable clothing and leave your schedule open afterward.
  • Bring your insurance information, medication list, and questions.
  • Let us know early if transportation, childcare, work obligations, or cost concerns may affect attendance.

Research protocols involving ketamine and esketamine are not all identical. A systematic review of clinical protocols found meaningful variation in scheduling and clinical approaches across studies (Freind et al., 2023). That is why your own plan should come from the clinician overseeing your care, not from an online schedule or another person’s experience.

Questions worth bringing to your first conversation

It is reasonable to want specifics before making time for a monitored appointment. We encourage you to ask direct questions, including:

  • What should I eat, drink, or avoid before my appointment?
  • Which medications or supplements should I review with you?
  • How long should I expect to be in the clinic?
  • What will you monitor during the observation period?
  • What effects should prompt me to tell the team right away?
  • How should I arrange transportation home?
  • What happens if I need to reschedule?
  • How will follow-up visits and medication review fit into my overall care?

Our medication management visits can be an important place to discuss changing symptoms, tolerability, and the rest of your medication plan. Published trials can offer useful context, but they do not replace an individualized conversation. For example, a randomized study of intranasal esketamine included structured follow-up and safety assessment, illustrating the value of ongoing clinical oversight in this kind of care (Popova et al., 2019).

Keep expectations grounded in your own care plan

It can be tempting to compare services, read personal stories, and search for a simple prediction about what will happen. Those sources can raise helpful questions. They cannot tell us how your health history, medications, transportation needs, or day-to-day circumstances will shape your appointment.

You may also encounter information about IV ketamine while researching SPRAVATO®. Ketamine is FDA-approved as an anesthetic. Its use for depression or other psychiatric conditions is off-label, meaning it is not FDA-approved for those psychiatric uses. Reviews of ketamine in mood-disorder care discuss both its clinical interest and the need for careful assessment and monitoring (Park et al., 2019).

Even research comparisons need to be read carefully. A recent retrospective review comparing IV ketamine and intranasal esketamine identified patterns in clinical records, but its design cannot answer every question about why individual experiences differ. Those limits are reflected in comparative chart-review research (Meisner et al., 2025). Your visit is a clinical encounter, not a replication of a study protocol.

The useful question is not whether your experience will match someone else’s. It is whether you understand the process, have a safe transportation plan, and feel able to speak openly with us about what you need. You can review our SPRAVATO® care information and contact our team when you are ready to discuss scheduling.

If you are in immediate danger, are thinking about harming yourself or someone else, or cannot stay safe, call 911, go to the nearest emergency room, or call or text 988 to reach the 988 Suicide & Crisis Lifeline for 24/7 support in the United States (988 Suicide and Crisis Lifeline, n.d.).

Works Cited

  1. DeBattista C, et al. The Black Book of Psychotropic Dosing and Monitoring. https://pubmed.ncbi.nlm.nih.gov/38993656/
  2. Freind JM, et al. Therapeutic Protocols Using Ketamine and Esketamine for Depressive Disorders: A Systematic Review. https://pubmed.ncbi.nlm.nih.gov/37638529/
  3. Popova V, et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression. https://pubmed.ncbi.nlm.nih.gov/31109201/
  4. Park LT, et al. Ketamine for Treatment-Resistant Mood Disorders. https://pubmed.ncbi.nlm.nih.gov/31975953/
  5. Meisner R, et al. Comparative Effects of Repeated Ketamine Infusion Versus Intranasal Esketamine in Patients With Treatment-Resistant Depression: A Retrospective Chart Review. https://pubmed.ncbi.nlm.nih.gov/41004170/
  6. 988 Suicide and Crisis Lifeline. https://988lifeline.org/

Disclaimer

This article is for educational purposes only and is not a substitute for individualized evaluation, diagnosis, or treatment from a qualified healthcare professional.

Share Now

Request a Psychiatric Appointment

You can begin with a question, a concern, or a change you would like help understanding. Whether you are seeking care for yourself or your child, we welcome your questions about our services.

Call 754-287-5443 or submit an appointment request. Our team will respond to your request.